Conference Coverage
Conference Coverage
Lymphoma Debate: CAR T Not a Clear Winner
Fiercely debating on best strategies for treating advanced lymphoma, specialists could not reach consensus.
Conference Coverage
Expert Updates Therapy for Waldenström Macroglobulinemia
A specialist applies a novel, nuanced approach to Waldenström macroglobulinemia, based on mutational status.
Feature
Cannabis in Cancer: What Oncologists and Patients Should Know
Access to and use of cannabis alongside cancer care have outpaced the science on evidence-based indications, according to an ASCO expert panel.
Feature
Many Hurdles Exist to Treating Lung Cancer With CAR T Cells
Unleashing the immune system in a highly specific manner, ‘is obviously, in a way, a holy grail’ in lung cancer, said an expert at the W...
Conference Coverage
Myeloma: Isa-KRd Induction Shows High MRD Responses
Interim analysis of first MIDAS trial findings shows “highest rate of response and MRD negativity to date.”
Conference Coverage
Adding Short-term ADT to High-Dose Radiotherapy Benefits Some Prostate Cancers
Patients with intermediate- or high-risk localized prostate cancer who had PSA levels under 30 ng/mL and no clinical involvement of the seminal...
Latest News
Mycosis Fungoides: Measured Approach Key to Treatment
Topical/skin-directed therapies are best for early-stage disease or in combination with systemic therapies in advanced disease, according to Dr....
Conference Coverage
Isatuximab Quadruplet Approval Could Change the Landscape for Treating Myeloma
Findings of phase 3 IMROZ trial demonstrated the efficacy of Isa-VRd, a four-drug combo, in treating patients newly diagnosed with myeloma.
Conference Coverage
IMRT vs Proton Therapy for Early Prostate Cancer?
The results of a new trial demonstrate ‘equivalent outcomes, with superb cancer control rates and extremely low toxicity from both treatments.’
Conference Coverage
NCCRT Confirmed as Best Approach in Locally Advanced, Resectable ESCC
Researchers compred neoadjuvant concurrent chemoradiotherapy with adjuvant sequential chemoradiotherapy (ASCRT) in locally advanced esophageal...
Conference Coverage
MM: First CAR T-Cell Therapy to Exhibit OS Benefit
CARTITUDE-4 study update indicated that CAR T-cell therapy improves overall survival in relapsed/refractory multiple myeloma.